Bevacizumab and adebrelimab for MSS colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining two drugs—bevacizumab and adebrelimab—can help people with a specific type of colorectal cancer that has spread and is MSS-type. It's for patients who have already had standard chemotherapy and have tumors that show certain genetic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your colorectal cancer has spread and is MSS-type (a lab result from your tumor tissue).
- Your tumor has a specific genetic pattern called MCRIH, found by a special test.
- You have at least one tumor that can be measured on a scan.
- You are able to get out of bed and care for yourself (ECOG score 0 or 1).
- Your blood counts and liver/kidney function are within certain ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new drug (HRS-2189) combined with two other medications (Adebrelimab and BP102) for people whose colorectal cancer has spread. It aims to see if this combination can help control the cancer.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.